OptiNose, Inc. (OPTN)
| Market Cap | 198.26M |
| Revenue (ttm) | 77.93M |
| Net Income (ttm) | -75.31M |
| Shares Out | 111.38M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133,763 |
| Open | 1.74 |
| Previous Close | 1.73 |
| Day's Range | 1.72 - 1.83 |
| 52-Week Range | 1.60 - 4.30 |
| Beta | -0.24 |
| Analysts | Buy |
| Price Target | 5.71 (+220.79%) |
| Earnings Date | Mar 6, 2023 |
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also... [Read more]
Full Company ProfileFinancial Performance
In 2021, OptiNose's revenue was $74.65 million, an increase of 51.99% compared to the previous year's $49.12 million. Losses were -$82.30 million, -17.53% less than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for OPTN stock is "Buy." The 12-month stock price forecast is $5.71, which is an increase of 220.79% from the latest price.
News
Optinose Appoints Paul Spence as Chief Commercial Officer
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...
Optinose Announces Departure of Acting Chief Financial Officer
YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...
Optinose Announces Proposed Public Offering of Common Stock and Warrants
YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical Rhinology ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical Rhinology
OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
Company reports second quarter XHANCE net revenue of $20.6 million increased 12%
Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern Time
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trials to reduce exacerbations for patients with chronic sinusitis
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis
Optinose Stock Moves Higher On Positive Second Chronic Sinusitis Phase 3 Trial
Optinose Inc (NASDAQ: OPTN) announced the statistically significant benefits of XHANCE in the ReOpen2 trial for the symptoms co-primary endpoint and the CT scan co-primary endpoint. Significant impro...
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients
Optinose Announces Departure of Chief Financial Officer
Michele Janis Appointed Acting Chief Financial Officer
OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -29.17% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Optinose Reports First Quarter 2022 Financial Results and Operational Updates
Company reports first quarter XHANCE net revenue of $14.8 million increased 35% compared to first quarter 2021
Optinose Announces Reporting Date for First Quarter 2022 Financial Results
Conference Call and Webcast to be held May 12, 2022, at 8:00 a.m. Eastern Time
Optinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha...
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 4.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million
Optinose's XHANCE Meets Primary Endpoints In Chronic Sinusitis Trial
Optinose Inc (NASDAQ: OPTN) has announced positive data from the ReOpen1 Phase 3 trial of Xhance (fluticasone propionate) Exhalation Delivery System in chronic sinusitis. The trial met both of its co-...